

## Pharmacy Services

(800) 522-0114, option 4

October 5, 2016

Dear SoonerCare Provider,

Effective October 5, 2016, SoonerCare will remove the prior authorization for Neulasta® (pegfilgrastim). Numerous inquiries regarding the prior authorization of Neulasta® were received by SoonerCare, and after a review of data the decision was made to remove the prior authorization requirement. SoonerCare reserves the right to reinstate the prior authorization of Neulasta® in the future.

The prior authorization for Granix® (tbo-filgrastim) and Zarxio™ (filgrastim-sndz) will remain in place. The prior authorization criteria are located on the OHCA website on the Pharmacy Prior Authorization page at [www.okhca.org/pa](http://www.okhca.org/pa) in the biologic therapeutic category and are as follows:

- An FDA approved diagnosis; and
- A patient-specific, clinically significant reason why the member cannot use Neupogen® (filgrastim) or Neulasta® (pegfilgrastim).

Neupogen® and Neulasta® **will not** require a prior authorization.

If the member requires Granix® (tbo-filgrastim) or Zarxio™ (filgrastim-sndz) through either a pharmacy or medical claim a manual prior authorization form must be submitted. The prior authorization forms can be located on the forms page on the OHCA website at [www.okhca.org/forms](http://www.okhca.org/forms). Please use PHARM-04 for pharmacy requests and PHARM-18 for medical requests.

All medication prior authorization requests are processed by the pharmacy authorization unit whether the drug is ultimately provided through a physician's office, outpatient clinic, or pharmacy.

If you have questions, please contact the pharmacy authorization unit at (800) 522-0114, option 4.

Thank you for your continued service to Oklahoma's SoonerCare members.